Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: StemCell Institute Inc.

Market Cap 6.85B 42.79M 36.96M 34.06M 31.88M 59.75M 4.07B 60.67M 402M 157M 1.98B 161M 157M P/E Ratio 2026
49.6x
P/E Ratio 2027 * 61.4x
Enterprise Value 6.85B 42.79M 36.96M 34.06M 31.88M 59.75M 4.07B 60.67M 402M 157M 1.98B 161M 157M EV / Sales 2026
2.79x
EV / Sales 2027 * 2.21x
Free-Float
23.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.59%
1 week-1.18%
Current month+2.45%
1 month-1.91%
3 months-19.40%
6 months-14.23%
Current year-15.64%
1 week 643
Extreme 643
678
1 month 627
Extreme 627
694
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,245
3 years 627
Extreme 627
3,285
5 years 627
Extreme 627
3,610
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 2016-05-31
Director TitleAgeSince
Director/Board Member 66 2020-05-31
Director/Board Member 53 2013-08-31
Director/Board Member 81 2015-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-1.18%-36.65%-75.47% 43.05M
-1.19%+3.76%+48.77%+44.94% 130B
+0.72%+7.92%+5.79%+36.39% 85.89B
+3.13%+5.23%-11.66%+52.41% 24.57B
-0.55%+2.34%+10.85%+47.10% 22.48B
-0.57%+0.98%+0.24%+14.76% 21.83B
+1.16%+2.10%-13.01%-20.18% 20.16B
+2.06%+9.65%+8.83%+128.60% 15.04B
+1.26%+5.44%-2.87%+3.48% 14.78B
+0.43%+9.10%+52.03%+115.41% 13.4B
Average +0.59%+3.39%+6.23%+34.75% 34.83B
Weighted average by Cap. +0.11%+4.43%+21.04%+42.39%

Financials

2026 2027 *
Net sales 2.87B 17.92M 15.47M 14.26M 13.35M 25.01M 1.7B 25.4M 168M 65.65M 829M 67.24M 65.81M 3.1B 19.35M 16.71M 15.4M 14.42M 27.02M 1.84B 27.44M 182M 70.91M 895M 72.63M 71.08M
Net income 180M 1.12M 971K 894K 837K 1.57M 107M 1.59M 10.56M 4.12M 51.99M 4.22M 4.13M 110M 687K 593K 547K 512K 959K 65.27M 974K 6.45M 2.52M 31.77M 2.58M 2.52M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
26-06-15 669.00 ¥ -0.59% 5,000
26-06-12 673.00 ¥ -0.15% 10,300
26-06-11 674.00 ¥ +2.12% 3,600
26-06-10 660.00 ¥ +0.30% 7,300
26-06-09 658.00 ¥ +0.61% 6,600

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!